<DOC>
	<DOCNO>NCT01175135</DOCNO>
	<brief_summary>This study aim evaluate whether PF-02545920 safe effective treatment acute exacerbation schizophrenia 4-week inpatient treatment period . The study use Positive Negative Syndrome Scale ( PANSS ) measure change symptoms PF-02545920 compare risperidone placebo treatment .</brief_summary>
	<brief_title>An Inpatient Study Of The Efficacy , Safety , And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Diagnosis schizophrenia acute exacerbation illness The current acute exacerbation schizophrenia must less 4 week duration prior initial evaluation . Subjects evidence history clinically significant uncontrolled medical illness Subjects current diagnosis schizoaffective disorder , major depression , bipolar disorder , obsessive compulsive disorder . Subjects meet Diagnostic Statistical ManualIV ( DSMIV ) define diagnostic criterion psychoactive substance dependence ( exclude nicotine dependence ) within 12 month screen DSMIV define substance abuse within 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>acute exacerbation</keyword>
	<keyword>inpatient</keyword>
</DOC>